ICICI Securities Maintains Buy Ratings on Pfizer and Akums with Updated Targets
ICICI Securities released research reports on Pfizer and Akums Drugs and Pharmaceuticals for Q2FY27. Pfizer reported a 13.2% revenue increase driven by key brands despite discontinuing Minipress XL sales in India, with gross margins contracting but offset by lower costs. The target price was lowered to INR 4,800. Akums showed strong growth with a 38.6% rise in CDMO revenue, margin improvements, and expansion plans in exports, leading to a higher target price of INR 925. Both stocks received a BUY rating.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 30/100.
Outlets measured: moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (58–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 4 Nov, 03:16 pm. Other outlets followed.
- 1